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Abstract. Anti-angiogenic therapies targeting vascular endo-
thelial growth factor (VEGF) and its receptor (VEGF-R) are 
important treatments for a number of human malignancies, 
including colorectal cancers. However, there is increasing 
evidence that VEGF/VEGF-R inhibitors promote the adap-
tive and evasive resistance of tumor cells to the therapies. The 
mechanism by which the cancer cells become resistant remains 
unclear. One potential mechanism is that VEGF/VEGF-R 
blockers directly act on tumor cells independently of anti-
angiogenic effects. In this study, the direct effects of an 
anti-VEGF antibody (bevacizumab) and a VEGF-R tyrosine 
kinase inhibitor (sunitinib) on the evasive adaptation of colon 
cancer cells were compared. HCT116 and RKO human colon 
cancer cell lines were chronically exposed (3 months) to beva-
cizumab or sunitinib in vitro to establish bevacizumab- and 
sunitinib-adapted cells, respectively. Transwell migration and 
invasion assays, western blotting, reverse transcription-quan-
titative polymerase chain reaction, co-immunoprecipitation 
analysis, cell survival assays and ELISAs were conducted 
to analyze the adapted cells. Compared with the control 
vehicle-treated cells, the two cell models exhibited increased 
migration and invasion activities to different degrees and 
through different mechanisms. The bevacizumab-adapted 
cells, but not in the sunitinib-adapted cells, exhibited redun-
dantly increased expression levels of VEGF/VEGF-R family 
members, including VEGF-A, placental growth factor, 
VEGF-C, VEGF-R1 and VEGF-R3. In addition, the phos-
phorylation levels of VEGF-R1 and VEGF-R3 were increased 
in the bevacizumab-adapted cells compared with the control 
cells. Thus, the inhibition of VEGF-R1 and VEGF-R3 
decreased the evasive activities of the cells, suggesting that 
they remained dependent on redundant VEGF/VEGF-R 
signaling. By contrast, the sunitinib-adapted cells exhibited 
increased neuropilin-1 (NRP1) expression levels compared 
with the control cells. In the sunitinib-adapted cells, NRP1 
interacted with phosphorylated cMet, and the cMet activa-
tion was dependent on NRP1. Thus, NRP1 or cMet blockade 
suppressed the evasive activation of the sunitinib-adapted 
cells. These results suggest that the sunitinib-adapted cells 
switched from a VEGF-R-dependent pathway to an alternative 
NRP1/cMet-dependent one. The findings of the present study 
indicate that VEGF/VEGF-R inhibitors directly act on colon 
cancer cells and activate their evasive adaptation via different 
mechanisms.
Introduction
Vascular endothelial growth factor (VEGF) and VEGF-
receptor (VEGF-R) family members are the central regulators 
of tumor angiogenesis (1). Therefore, several angiogenesis 
inhibitors targeting the VEGF/VEGF-R pathway have been 
developed and have become an important option for the 
management of a number of human malignancies, including 
colorectal cancer (1-4). However, there is increasing evidence 
that the clinical results of VEGF/VEGF-R-targeted thera-
pies are very modest, resulting in a moderate improvement 
in overall survival (5-8). Pre-clinical studies have shown 
that VEGF/VEGF-R-targeting agents accelerate invasion 
and metastasis (9,10). Additionally, the clinical outcome 
is associated with the development of resistance to the 
VEGF/VEGF-R-targeting agents and the increased risk of 
invasion and metastasis (11-14). Therefore, acquired and 
evasive resistance to VEGF/VEGF-R inhibitors is a growing 
concern in the clinic.
Several mechanisms by which tumor cells acquire 
resistance to VEGF/VEGF-R pathway targeting therapies 
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and escape from aggravated microenvironments have been 
elucidated (1-4,11). VEGF/VEGF-R blockers primarily target 
vascular endothelial cells and inhibit tumor angiogenesis, 
leading to hypoxia within the tumor. Therefore, hypoxic 
stress is considered to be a central mechanism for the aggres-
sive malignant progression of tumor cells (15-17). Several 
preclinical studies have shown that VEGF pathway inhibitors 
facilitate tumor cell invasion and metastasis, which require 
hypoxic conditions and hypoxia-inducible factors (9-11).
Tumor cells are important targets of VEGF/VEGF-R 
inhibitors, as several types of cancer cells express func-
tional VEGF-Rs and utilize VEGF as an autocrine survival 
factor (18-22). Therefore, it is possible that VEGF/VEGF-R 
blockers could directly act on tumor cells and elicit an adaptive 
and evasive response, resulting in more aggressive phenotypes. 
Notably, several studies, including one by the present research 
group, have shown that the chronic treatment of colon cancer 
cells with anti-VEGF-A antibody alters their phenotype, for 
example, by increasing cell motility, apoptosis resistance 
under hypoxic conditions and spheroid formation (19-22).
VEGF/VEGF-R-targeting agents are classified into 
the following two groups: Those that target VEGF ligands 
[VEGF-A, VEGF-B and placental growth factor (PlGF)], such 
as bevacizumab and aflibercept, and those that target VEGF-Rs 
(VEGF-R1, -R2 and -R3), including sunitinib, sorafenib, 
regorafenib, pazopanib, axitinib, vandetanib, dovitinib, nint-
edanib, lenvatinib, foretinib and cabozantinib (5-7). The aim 
of the present study was to elucidate whether bevacizumab 
(a VEGF-A inhibitor) and sunitinib (a blocker of all VEGF-
Rs) directly affect the evasive adaptation of tumor cells. The 
different mechanisms of evasive activation of the two drugs 
were also investigated. For this aim, VEGF/VEGF-R inhib-
itor-adapted cells were developed via the prolonged (3 months) 
exposure of human colon cancer cell lines to bevacizumab 
(bevacizumab-adapted cells) or sunitinib (sunitinib-adapted 
cells). This experiment was based on the observation of tumor 
invasiveness occurring within a few months of the initiation 
of treatment with VEGF/VEGF-R-targeting agents in several 
preclinical models. Notably, preclinical studies have demon-
strated that extensive treatment (1-3 months) with sunitinib 
accelerates local invasion and distant metastasis and leads to a 
shortening of overall survival (9,10).
Materials and methods
Reagents. Sunitinib (a VEGF-R tyrosine kinase inhibitor), 
foretinib [a tyrosine-protein kinase Met (cMet) and VEGF-R 
tyrosine kinase inhibitor], capmatinib (a selective inhibitor of 
cMet), Gw788388 [a selective inhibitor of transforming growth 
factor (TGF)β-RI and -RII], SSR128129E [an allosteric fibro-
blast growth factor receptor (FGF-R) 1-3 inhibitor], CP-673451 
[a selective inhibitor of platelet-derived growth factor receptor 
(PdGF-R)-α/β] and V1/A7R [a neuropilin-1 (NRP1)-binding 
heptapeptide, ATwLPPR, that specifically inhibits NRP1) 
were obtained from Selleck Chemicals (Cosmo Bio Co., Ltd., 
Tokyo, Japan). Neutralizing antibodies against human hepato-
cyte growth factor (HGF; MAB294), human NRP1 (AF3870), 
control non-immune sheep IgG (5-001-A) and control non-
immune mouse IgG (MAB002) were from R&d Systems, 
Inc. (Minneapolis, MN, USA). Specific antagonistic inhibitors 
for VEGF-R1 and VEGF-R3 were purchased from Genscript 
Japan, Inc. (Tokyo, Japan).
Establishment of cell models adapted to bevacizumab and 
sunitinib. Human colon cancer cell lines (HCT116 and RKO) 
were obtained from American Type Culture Collection 
(Manassas, VA, USA) and maintained in RPMI-1640 medium 
(Nacalai Tesque, Inc., Tokyo, Japan) with 10% fetal bovine 
serum (FBS; SAFS Biosciences; Merck KGaA, darmstadt, 
Germany), 100 U/ml penicillin and 0.1 mg/ml streptomycin 
(both from Nacalai Tesque, Inc.) at 37˚C under 5% CO2 and 
95% air. To establish the bevacizumab-adapted cells (HCT/bev 
and RKO/bev, respectively), cells were chronically exposed 
to bevacizumab (Chugai Pharmaceuticals Co., Ltd., Tokyo, 
Japan) for 3 months at a clinically relevant dose (100 µg/ml), 
based on the US Food and drug Administration-approved 
bevacizumab dose (5 mg/kg) corresponding to a concentration 
of 100 µg/ml in cell culture experiments (20). To develop the 
sunitinib-adapted cells (HCT/suni and RKO/suni, respectively) 
or foretinib-adapted cells (HCT/fore and RKO/fore, respec-
tively), cells were chronically treated with a pharmacologically 
relevant concentration of sunitinib (0.1 µM) or foretinib 
(5 nM) for 3 months (23,24). The vehicle-treated control cells 
(HCT/ctl and RKO/ctl, respectively) were obtained by chronic 
treatment with dMSO (0.005%) for 3 months.
The bevacizumab-adapted cells were pretreated with dMSO 
(0.005%), VEGF-R1 inhibitor (50 µM) or VEGF-R3 inhibitor 
(75 µM) for 1 h at 37˚C, and then their migration and invasion 
abilities were determined. The control and sunitinib-adapted 
cells were pretreated with vehicle (dMSO, 0.005%), capma-
tinib (2 nM), Gw788388 (0.35 µM), SSR128129E (0.2 µM), 
CP-673451 (0.05 µM), NRP1 antagonist V1/A7R (3 µM), anti-
NRP1 neutralizing antibody (5 µg/ml), anti-HGF neutralizing 
antibody (1 µg/ml), a control non-immune sheep IgG (5 µg/ml; 
as a control for anti-NRP1 neutralizing antibody) or a control 
non-immune mouse IgG (1 µg/ml; as a control for anti-HGF 
neutralizing antibody) for 1 h at 37˚C, and then their migra-
tion and invasion activities were evaluated. Parental HCT116 
and RKO cells were pretreated with vehicle (dMSO, 0.005%), 
sunitinib (0.1 µM) or foretinib (10 nM) for 48 h at 37˚C, then 
their migration and invasion activities were examined.
Cell migration and invasion assay. Equal numbers of 
cells (50,000 cells) were suspended in 0.25 ml RPMI-1640 
containing 1% FBS with various treatment agents, as 
described in the section entitled ‘establishment of cell models 
adapted to bevacizumab and sunitinib’, and then placed in 
the top compartment of an uncoated 8-µm pore membrane 
chamber (Bd Biosciences, Franklin Lakes, NJ, USA); 0.75 ml 
RPMI-1640 containing 4% FBS for the migration assay or 
10% FBS for the invasion assay was added to the bottom 
compartment. Following 24-48 h incubation under standard 
conditions (37˚C/5% CO2), non-migrating cells were scraped 
from the top compartment, and cells that had migrated to the 
bottom compartment were fixed with 100% methanol at 25˚C 
for 30 sec, and stained at 25˚C for 30 sec using Hemacolor 
Rapid staining of blood smear (Merck KGaA). Membranes 
were excised and mounted on a standard microscope slide. The 
numbers of migrated cells were determined from 4-6 random 
high-power fields visualized at x20 magnification.
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Invasion assays were performed using a protocol similar 
to that of the migration assay with minor modifications. The 
inserts used in the invasion assays were coated with Matrigel 
(Bd Biosciences) and prehydrated with 1% FBS-supplemented 
medium for 2 h prior to the addition of the cell suspen-
sion. Following 48-h incubation under standard conditions 
(37˚C/5% CO2), the numbers of invading cells were quantified 
as described above.
Reverse transcription-quantitative polymerase chain reaction 
(RT-qPCR). The extraction of total RNA was carried out using 
an RNeasy mini kit (Qiagen, Tokyo, Japan), and total RNA 
(1 µg) was used to synthesize cdNA using the PrimeScript RT 
reagent kit (Takara Bio, Inc., Tokyo, Japan) according to the 
following steps: 37˚C for 10 min, 85˚C for 30 sec, and cooling 
down to 4˚C. The levels of transcripts for human NRP1 and 
human GAPDH in the cells were measured by RT-qPCR using 
the following specific primer sets: NRP1, 5'-CCCTGAGAA 
TGGGTGGACT-3' (forward) and 5'-CGTGACAAAGCGCAG 
AAG-3' (reverse); GAPDH, 5'-GCTAGGGACGGCCTGAAG-3' 
(forward) and 5'-GCCCAATACGACCAAATCC-3' (reverse). 
qPCR analysis was performed using a SYBR-Green Master 
Mix (Applied Biosystems; Thermo Fisher Scientific, Inc., 
Waltham, MA, USA) according to the following steps: 95˚C for 
30 sec (1 cycle), 60˚C for 30 sec and 95˚C for 5 sec (40 cycles). 
Amplification and quantification of the PCR products were 
performed using the Applied Biosystems 7500 System (Applied 
Biosystems; Thermo Fisher Scientific, Inc.). Standards were run 
in the same plate and the relative standard curve quantification 
method was used to calculate the relative mRNA expres-
sion (25). RNA quantities were normalized against the GAPDH 
mRNA levels.
Western blot analysis. Total cell lysates were prepared using 
a lysis buffer containing 100 mM Tris-HCl (pH 6.8), 300 mM 
NaCl, 2 mM EdTA and 4% (v/v) sodium dodecylsulfate (SdS). 
Protein concentrations were determined using a bicincho-
ninic acid protein assay (Pierce; Thermo Fisher Scientific, 
Inc.).  The cell extracts (50 µg protein/lane) were subjected 
to 10% SdS-polyacrylamide gel electrophoresis (PAGE) 
and transferred to a polyvinylidene difluoride membrane 
(EMd Millipore, Bedford, MA, USA). The membrane was 
blocked with 4% skimmed milk for 1 h at 25˚C, and then 
incubated for 15 h at 4˚C in phosphate-buffered saline (PBS) 
containing 0.05% Tween-20 with the primary antibody 
according to the instructions provided by the manufacturer; 
a rabbit monoclonal anti-human NRP1 antibody (d62C6) 
at 1:3,000 dilution, a rabbit monoclonal anti-human cMet 
antibody (d1C2) at 1:2,000 dilution, a rabbit monoclonal 
anti-human phospho-cMet (Tyr1234/Tyr1235) antibody (d26) 
at 1:3,000 dilution, a rabbit monoclonal anti-human p130Cas 
antibody (E1L9G) at 1:2,000 dilution, a rabbit monoclonal 
anti-human phospho-p130Cas (Tyr410) antibody (#4011) 
at a 1:1,000 dilution, a rabbit monoclonal anti-human Slug 
antibody (C19G7) at a 1:1,000 dilution, a rabbit monoclonal 
anti-human N-cadherin antibody (d4R1H) at a 1:2,000 dilu-
tion and a mouse monoclonal anti-human β-actin antibody 
(8H10d10) at a 1:10,000 dilution. All primary antibodies 
were acquired from Cell Signaling Technology, Inc. (danvers, 
MA, USA). The membrane was probed for 1 h at 25˚C with 
secondary antibodies; anti-rabbit IgG horseradish peroxidase 
(HRP)-linked antibody at a 1:10,000 dilution (#7074) and 
anti-mouse IgG HRP-linked antibody at a 1:10,000 dilution 
(#7076) (both from Cell Signaling Technology, Inc.). The 
membranes were developed using ECL western blot detection 
reagents (GE Healthcare Life Sciences, Little Chalfont, UK).
Co-immunoprecipitation analysis. For NRP1/cMet 
co-immunoprecipitation analysis, cells were crosslinked 
with dithiobis(succinimidyl propionate) (Pierce; Thermo 
Fisher Scientific, Inc.) prior to cell lysis. Cells were harvested 
in ice-cold lysis buffer (50 mM HEPES, pH 7.0, 150 mM 
NaCl, 10 mM EdTA, 1.5 mM MgCl2, 1% Nonidet P-40, 
1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM 
sodium orthovanadate, 0.5% sodium deoxycholate, 5 mg/ml 
aprotinin, 5 mg/ml leupeptin, 20 mM sodium fluoride and 
20 mM sodium pyrophosphate), homogenized through a 
23-gauge needle 10 times, then centrifuged at 10,000 x g for 
20 min at 4˚C. The clarified lysate (1 mg) was incubated with 
a rabbit monoclonal anti-human NRP1 antibody (d62C6) 
overnight at 4˚C with constant gentle rocking, followed 
by the addition of Protein G magnet dynabeads (Thermo 
Fisher Scientific, Inc.) for 4 h at 4˚C. The immunoprecipitates 
were washed, eluted with SdS-PAGE sample buffer, and 
subjected to SdS-PAGE using 4-20% polyacrylamide gradient 
gels. They were transferred to a polyvinylidene difluoride 
membrane (EMd Millipore). The membrane was blocked with 
4% skimmed milk for 1 h at 25˚C, and then incubated for 15 h at 
4˚C in PBS containing 0.05% Tween-20 with the primary anti-
body; a rabbit monoclonal anti-human cMet antibody (d1C2) 
at 1:2,000 dilution, a rabbit monoclonal anti-human phospho-
cMet (Tyr1234/Tyr1235) antibody (d26) at 1:3,000 dilution, 
and rabbit monoclonal anti-human NRP1 antibody (d62C6) at 
1:3,000 dilution. All primary antibodies were acquired from 
Cell Signaling Technology, Inc. The membrane was probed 
for 1 h at 25˚C with anti-rabbit IgG HRP-linked antibody at a 
1:10,000 dilution (#7074; Cell Signaling Technology, Inc.). The 
membranes were developed using ECL western blot detection 
reagents (GE Healthcare Life Sciences).
Cell survival assay. Cell survival was assessed using a 
CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega Corporation, Madison, wI, USA), according to the 
manufacturer's protocol. Cells were plated (1x104 cells/well) in a 
96-well flat-bottom plate for 24 h, then they were treated with 
sunitinib (0.1, 1 or 10 µM) or with bevacizumab (10 or 100 µg/ml) 
for 3 days. Following treatment, 100 µl RPMI-1640 medium 
containing the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reagent 
(20 µl/well) was added to each well and the cells were incubated 
for 1 h at 37˚C. The levels of blue formazan were measured spec-
trophotometrically at 490 nm immediately using a microplate 
reader (wallac 1420 ARVO MX; PerkinElmer, Inc., waltham, 
MA, USA).
ELISA. Secreted VEGF ligands (VEGF-A, PlGF and VEGF-C) 
in the cell culture supernatants were measured using a VEGF 
isotype-specific ELISA kit (DVE00, DPG00 and DVEC00; 
R&d Systems, Inc.) according to the manufacturer's protocol. 
Notably, an ELISA that measures VEGF-B was not available 
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from R&d Systems, Inc. when the study was conducted. Total 
and phosphorylated VEGF-Rs (R1 and R3) in cell lysates were 
measured using the respective human VEGF-R duoSet IC 
ELISA kit and the respective human Phospho-VEGF-R duoSet 
IC ELISA kit (both from R&d Systems, Inc.) according to the 
manufacturer's protocol.
Statistical analysis. Results are expressed as the mean ± stan-
dard deviation. differences between groups were analyzed via 
analysis of variance and Scheffe's test using SPSS software 
(release 6.1; SPSS Japan, Tokyo, Japan). P<0.01 was consid-
ered to indicate a statistically significant difference.
Results
Development and characterization of sunitinib- and beva-
cizumab-adapted cells. The human colon cancer cell lines 
HCT116 and RKO were selected because they express several 
VEGF/VEGF-R family members and utilize autocrine VEGF 
signals for their survival; this has been demonstrated by several 
groups, including the present research team (20-22). To inves-
tigate the direct effects of sunitinib and bevacizumab, two 
cell models (sunitinib- and bevacizumab-adapted cells) were 
established by continuously culturing the cells in the presence 
of sunitinib or bevacizumab for 3 months; a similar procedure 
has been used in previous studies (21,22).
To characterize the resistance of the sunitinib-adapted 
cells (HCT/suni and RKO/suni) to sunitinib, the cells were 
treated with sunitinib at several concentrations and analyzed 
using a cell survival assay (Fig. 1A and B). A marked resis-
tance to sunitinib was observed in the sunitinib-adapted 
cells compared with the respective vehicle-treated control 
cells (Fig. 1A and B). However, the bevacizumab-adapted 
cells (HCT/bev and RKO/bev) exhibited similar growth rates 
to their respective control cells when treated with bevaci-
zumab (Fig. 1C and d).
Cell migration and invasion activities of the bevacizumab- 
and sunitinib-adapted cells. It has been reported that 
bevacizumab-adapted cells exhibit increased motility and 
invasive activities (21). Thus, these activities were compared 
in the bevacizumab- and sunitinib-adapted cells in the present 
study. A modified Boyden chamber assay demonstrated that 
the migration activities of the bevacizumab-adapted cells were 
significantly increased compared with those of the control 
cells (Fig. 2A-D). The sunitinib-adapted cells showed signifi-
cant increases in migration activities compared with those of the 
control and of the bevacizumab-adapted cells (Fig. 2A-d). Cell 
invasion was also examined using a Matrigel invasion assay. 
Consistent with the migration activity, the invasion activities 
of the bevacizumab-adapted cells were significantly increased 
compared with those of the control cells  Fig. 2E-H). The suni-
tinib-adapted cells exhibited significant increases in invasion 
activities compared with the control and with the bevacizumab-
adapted cells (Fig. 2E-H). These findings indicate that the 
evasive phenotype was more potently activated by the inhibition 
Figure 1. Characterization of the sunitinib- and bevacizumab-adapted cells. Survival of the control and sunitinib-adapted (A) HCT116 and (B) RKO cells in 
the absence or presence of sunitinib at the indicated concentrations. Survival of the control and bevacizumab-adapted (C) HCT116 and (d) RKO cells in the 
absence or presence of bevacizumab at the indicated concentrations. data are presented as the mean ± standard deviation (n=5). *P<0.01 vs. the respective 
vehicle (dimethylsulfoxide)-treated cells. HCT/ctl, control HCT116 cells; RKO/ctl, control RKO cells; HCT/suni, sunitinib-adapted HCT116 cells; RKO/suni, 
sunitinib-adapted RKO cells; HCT/bev, bevacizumab-adapted HCT116 cells; RKO/bev, bevacizumab-adapted RKO cells.
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of all VEGF-Rs compared with inhibition of the VEGF-A ligand 
alone and suggest that the evasive activation was induced by a 
different mechanism under the VEGF-R-inhibited conditions 
compared with the VEGF-A-inhibited conditions.
Different mechanisms of evasive adaptation in the bevaci-
zumab- and sunitinib-adapted cells. whether the mechanism 
of evasive adaptation differed between the bevacizumab- and 
sunitinib-adapted cells was investigated. It was hypothesized 
that the bevacizumab-adapted cells may redundantly depend 
on VEGF/VEGF-R family members aside from VEGF-A 
whereas the sunitinib-adapted cells may be independent 
of these proteins because all VEGF-Rs are inhibited in 
the cells. To test this hypothesis, the expression profiles of 
VEGF ligands and their receptors at the protein levels were 
compared in the two cell models using ELISAs. Consistent 
with the aforementioned hypothesis, the bevacizumab-adapted 
cells exhibited a significant increase in the expression levels 
of VEGF-A, PlGF, VEGF-C, VEGF-R1 and VEGF-R3 
compared with the control cells among the VEGF family 
members tested (Fig. 3A-E). Additionally, the phosphorylated 
levels of VEGF-R1 and VEGF-R3 were significantly elevated 
in the bevacizumab-adapted cells compared with the control 
cells (Fig. 3F and G), suggesting that the bevacizumab-adapted 
cells utilize VEGF-R1 and VEGF-R3 autocrine systems. 
By contrast, the sunitinib-adapted cells did not demonstrate 
any significant difference in the expression of VEGF family 
members when compared with the control cells (Fig. 3).
To investigate whether the bevacizumab-adapted cells 
utilized VEGF-R1 and VEGF-R3 systems for their evasive 
adaptation, specific antagonistic inhibitors for VEGF-R1 (26) 
or VEGF-R3 (27) were used. Treatment with the VEGF-R1 
inhibitor significantly decreased the migration and invasion 
activities of the HCT/bev and RKO/bev cells compared with 
the dMSO-treated controls (Fig. 4). when VEGF-R3 was 
blocked, the evasive activities of the HCT/bev and RKP/bev 
cells were also significantly inhibited compared with the 
dMSO-treated controls (Fig. 4). These results support the 
hypothesis that the bevacizumab-adapted cells were redun-
dantly dependent on VEGF family members.
To clarify the mechanism in the sunitinib-adapted cells, 
the present study focused on NRP1 as it is a multifunctional 
co-receptor involved in migration and invasion in several cancer 
cells (28-30). Thus, the expression levels of NRP1 were evaluated 
Figure 2. Effect of bevacizumab or sunitinib on migration and invasion activities. Migration of the control, bevacizumab-adapted and sunitinib-adapted 
(A) HCT116 and (B) RKO cells was determined by an uncoated Transwell migration assay (n=4-6; mean ± standard deviation). Representative photographs 
of the migrated (C) HCT116 and (d) RKO cells. Invasion of the control, bevacizumab-adapted and sunitinib-adapted (E) HCT116 and (F) RKO cells was 
determined by a Matrigel-coated Transwell invasion assay (n=4-6; mean ± standard deviation). Representative photographs of the invaded (G) HCT116 
and (H) RKO cells. *P<0.01 vs. the respective control cells; #P<0.01 vs. the respective bevacizumab-adapted cells. HCT/ctl, control HCT116 cells; RKO/ctl, 
control RKO cells; HCT/suni, sunitinib-adapted HCT116 cells; RKO/suni, sunitinib-adapted RKO cells; HCT/bev, bevacizumab-adapted HCT116 cells; 
RKO/bev, bevacizumab-adapted RKO cells; HPF, high power field.
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Figure 3. Expression of VEGF family members in the bevacizumab- and the sunitinib-adapted cells. Protein expression levels of (A) VEGF-A, (B) PlGF, 
(C) VEGF-C, (d) VEGF-R1, (E) VEGF-R3, (F) phosphorylated VEGF-R1 and (G) phosphorylated VEGF-R3 were measured using ELISAs. Values are 
shown as the levels relative to those of the respective control cells (n=3; mean ± standard deviation). *P<0.01 vs. the respective control cells. VEGF, vascular 
endothelial growth factor; PlGF, placental growth factor; VEGF-R, VEGF receptor.
Figure 4. Bevacizumab-adapted cells depend on VEGF-R1 and VEGF-R3. The bevacizumab-adapted cells were pretreated with dMSO, VEGF-R1 
inhibitor or VEGF-R3 inhibitor for 1 h, and then their (A) migration and (B) invasion abilities were determined in the presence of the respective agent 
(n=4-6; mean ± standard deviation). *P<0.01 vs. the dMSO-treated cells. VEGF-R, vascular endothelial growth factor receptor; dMSO, dimethylsulfoxide; 
HCT/bev, bevacizumab-adapted HCT116 cells; RKO/bev, bevacizumab-adapted RKO cells; HPF, high power field.
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in the sunitinib-adapted cells. As shown in Fig. 5A and B, NRP1 
expression was increased at the mRNA and protein levels in the 
sunitinib-adapted cells compared with the control cells.
To block NRP1 function, two different types of inhibitors 
[an NRP1 antagonistic peptide, which binds to the NRP1 extra-
cellular domain (31), and a neutralizing anti-NRP1 antibody] 
were used. Treatment with the NRP1 blockers significantly 
decreased the migration and invasion activities of the suni-
tinib-adapted cells but not the control cells when compared 
with the respective dMSO-treated controls (Fig. 5C-F). These 
results indicate that the sunitinib-adapted cells switched from 
a VEGF-R-dependent phenotype to an NRP1-dependent one.
Identification of the NRP1 partner receptor in the sunitinib-
adapted cells. The NRP1-dependent evasive mechanism in the 
sunitinib-adapted cells was investigated. NRP1 functions as 
a co-receptor for several growth factor receptors, including 
cMet, TGFβ-R, FGF-R and PdGF-R (28-30). To explore 
the partner receptor of NRP1, receptor kinase inhibitors 
specific for cMet (capmatinib), TGFβ-R (Gw788388), FGF-R 
(SSR128129E) and PdGF-R (CP-673451) were used. As shown 
in Fig. 6A and B, the inhibition of cMet, but not of TGFβ-R, 
FGF-R and PdGF-R, significantly reduced the migration 
activity of the sunitinib-adapted cells compared with that of 
the dMSO-treated control. By contrast, blocking cMet did not 
affect the control cells.
To further confirm the involvement of cMet in the evasive 
activation of the sunitinib-adapted cells, the effect of blocking 
the HGF derived from the cells was examined. As shown 
in Fig. 6C and d, the blockade of HGF with an anti-HGF 
Figure 5. Sunitinib-adapted cells depend on NRP1. (A and B) The expression of NRP1 was increased in the sunitinib-adapted cells. (A) Expression levels of 
NRP1 mRNA in the control and sunitinib-adapted cells were measured using reverse transcription-quantitative polymerase chain reaction (n=5; mean ± stan-
dard deviation). *P<0.01 vs. the respective control cells. (B) Representative western blot analysis of NRP1 protein expression levels in the control and the 
sunitinib-adapted cells (n=3). The levels of β-actin are shown as a loading control. (C-F) Effect of NRP1 blockade on the evasive activation of the sunitinib-
adapted cells. The control and the sunitinib-adapted cells were pretreated for 24 h with vehicle (dMSO), NRP1 antagonist or anti-NRP1 neutralizing antibody 
and their migration and invasion activities were evaluated. Migration activities of (C) HCT116 and (d) RKO cells and invasion activities of (E) HCT116 and 
(F) RKO cells are shown (n=4-6; mean ± standard deviation). *P<0.01 as indicated. NRP1, neuropilin-1; dMSO, dimethylsulfoxide; HCT/ctl, control HCT116 
cells; RKO/ctl, control RKO cells; HCT/suni, sunitinib-adapted HCT116 cells; RKO/suni, sunitinib-adapted RKO cells; HPF, high power field.
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neutralizing antibody significantly reduced the migration 
and invasion activities of the sunitinib-adapted cells but not 
the control cells compared with the respective IgG-treated 
control cells. These results are similar to those for cMet inhibi-
tion (Fig. 6A and B).
NRP1-dependent cMet activation in the sunitinib-adapted 
cells. The results observed in Figs. 5 and 6 suggest that NRP1 
participated in cMet activation in the sunitinib-adapted cells. 
To test this, the cMet phosphorylation levels were evaluated 
by immunoblot analysis. As shown in Fig. 7A, the levels of 
phospho-cMet were increased in the sunitinib-adapted cells 
compared with the control cells. whether NRP1 was required 
for cMet phosphorylation in the sunitinib-adapted cells was 
then investigated. Blocking NRP1 markedly reduced the 
levels of phosphorylated cMet (Fig. 7B) but did not affect the 
expression levels of total cMet in the sunitinib-adapted cells, 
indicating that cMet activation is dependent on NRP1.
To further investigate whether NRP1 physically inter-
acted with cMet and was associated with its activation in the 
sunitinib-adapted cells, immunoprecipitation in combination with 
immunoblot analysis was performed. NRP1 protein was immu-
noprecipitated, and then the levels of co-precipitated cMet and 
its phosphorylation were measured by immunoblot analysis. The 
association of NRP1 with cMet was increased in the sunitinib-
adapted cells compared with the control cells (Fig. 7C, upper 
panel). Importantly, the co-precipitation of phosphorylated cMet 
was observed only in the sunitinib-adapted cells (Fig. 7C, middle 
panel). These results indicate that NRP1 interacted with and was 
involved in cMet activation in the sunitinib-adapted cells.
The activation of the downstream effector of NRP1, 
p130Cas, which is an important NRP1 signaling molecule that 
activates cell motility (32) was also investigated. The levels 
of phospho-p130Cas were elevated in the sunitinib-adapted 
cells compared with the control cells (Fig. 7d, upper panel), 
while the levels of total p130Cas did not differ between the 
control and sunitinib-adapted cells (Fig. 7d, middle panel). As 
previous studies demonstrated that the activation of p130Cas 
is associated with the induction of the mesenchymal markers 
Slug and N-cadherin (33,34), the levels of these markers were 
Figure 6. cMet participates in the evasive activation of the sunitinib-adapted cells. Effect of the inhibition of cMet, TGFβ-R, FGF-R or PdGF-R on the migration 
activity in the sunitinib-adapted (A) HCT116 and (B) RKO cells. The control and sunitinib-adapted cells were pretreated for 24 h with vehicle (dMSO), cMet 
inhibitor (capmatinib), TGFβ-R inhibitor (Gw788388), FGF-R inhibitor (SSR128129E) or PdGF-R inhibitor (CP-673451), and the migration activity of the 
cells was analyzed (n=4-5; mean ± standard deviation). *P<0.01 vs. the respective dMSO-treated control cells. (C and d) Blockade of tumor cell-derived HGF 
suppresses the migration and invasion activities of the sunitinib-adapted cells. The control and sunitinib-adapted cells were pretreated for 24 h with a control 
non-immune IgG or anti-HGF neutralizing antibody, then their (C) migration and (d) invasion activities were evaluated (n=4-5; mean ± standard deviation). 
*P<0.01 vs. the respective control IgG-treated cells. cMet, tyrosine-protein kinase Met; TGFβ-R, transforming growth factor β receptor; FGF-R, fibroblast 
growth factor receptor; PdGF-R, platelet-derived growth factor receptor; dMSO, dimethylsulfoxide; HGF, hepatocyte growth factor; IgG, immunoglobulin G; 
Ab, antibody; HCT/ctl, control HCT116 cells; RKO/ctl, control RKO cells; HCT/suni, sunitinib-adapted HCT116 cells; RKO/suni, sunitinib-adapted RKO 
cells; HPF, high power field.
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evaluated in the sunitinib-adapted cells. Consistent with the 
activation of p130Cas, Slug and N-cadherin expression levels 
were increased in the sunitinib-adapted cells compared with 
the control cells (Fig. 7E).
Effect of dual blockade of VEGF-R and cMet on the evasive 
activation. Based on the aforementioned findings, it was 
hypothesized that the dual blockade of VEGF-R and cMet 
would inhibit the NRP1/HGF/cMet adaptive pathway under 
VEGF-R inhibition conditions. To test this, foretinib was used; 
this compound inhibits VEGF-R and cMet activities with nano-
molar potency (24). Short-term treatment with foretinib for 48 h 
did not activate the migration and invasion activities of HCT116 
and RKO cells (Fig. 8A and B). By contrast, treatment with suni-
tinib for 48 h significantly elevated these activities compared 
with those of the dMSO-treated control (Fig. 8A and B).
The effect of chronic foretinib exposure for 3 months on the 
evasive activities of the cells was then evaluated. A foretinib-
adapted cell model (HCT/fore and RKO/fore) similar to the 
sunitinib cell model was established. However, the foretinib-
adapted cells exhibited a marked activation of migration and 
invasion, similar to the sunitinib-adapted cells (Fig. 8C and d).
Finally, whether blocking NRP1 was effective in reducing 
the migration and invasion of the foretinib-adapted cells 
was examined. Notably, the blockade of NRP1 significantly 
decreased the migration and invasion activities in these 
cells compared with the IgG-treated control (Fig. 8E and F), 
suggesting that the foretinib-adapted cells retained a depen-
dence on NRP1.
Discussion
In the present study, the direct effects of two different VEGF 
pathway-targeting drugs, sunitinib and bevacizumab, on the 
evasive adaptation of colon cancer cells were compared. The 
results demonstrated that sunitinib activated the migration and 
Figure 7. NRP1-dependent cMet activation in the sunitinib-adapted cells. (A) Expression levels of phosphorylated cMet and total cMet were measured by 
western blot analysis. (B) NRP1-dependent cMet phosphorylation in the sunitinib-adapted cells. The sunitinib-adapted cells were pretreated for 2 h with 
vehicle (dMSO), NRP1 antagonist or anti-NRP1 neutralizing antibody, and then analyzed by western blotting using antibodies against phospho-cMet and 
total cMet, respectively. (C) Interaction of NRP1 with phosphorylated cMet in the sunitinib-adapted cells. NRP1 was immunoprecipitated with anti-NRP1 
antibody using cell lysates from the control and the sunitinib-adapted cells. Immunoblotting was performed using antibodies against phospho-cMet, total cMet 
and NRP1. western blot analyses were also conducted to determine the expression levels of (d) phosphorylated p130Cas and total p130Cas and (E) Slug and 
N-cadherin. (A, B, d and E) The levels of β-actin are shown as a loading control. NRP1, neuropilin-1; cMet, tyrosine-protein kinase Met; dMSO, dimethyl-
sulfoxide; Ab, antibody; HCT/ctl, control HCT116 cells; RKO/ctl, control RKO cells; HCT/suni, sunitinib-adapted HCT116 cells; RKO/suni, sunitinib-adapted 
RKO cells; IP, immunoprecipitation; wB, western blot.
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invasion activities of the cells more strongly than did bevaci-
zumab, and by a distinct mechanism. Under the bevacizumab 
VEGF-A ligand-blocking conditions, cancer cells remained 
dependent upon the VEGF-R1 and -R3 pathways, as their 
evasive abilities were significantly decreased by the specific 
inhibitors of VEGF-R1 and -R3 (Fig. 3F and G). This result 
is supported by a previous study (21), in which a pan-VEGF-R 
inhibitor, SU5416, suppresses the motility of bevacizumab-
adapted cells. By contrast, when all VEGF-Rs were inhibited 
by sunitinib, cancer cells became dependent on NRP1 and 
switched from a VEGF-R-dependent pathway to an alternative 
adaptive one (the NRP1/HGF/cMet pathway) (Figs. 6 and 7).
The present study revealed that NRP1 was required for cMet 
activation under conditions where all VEGF-Rs were inhibited 
by sunitinib. Previous studies have demonstrated that cMet is 
a critical receptor for the induction of evasive resistance to 
VEGF/VEGF-R inhibitors in several cancer models (35-37); 
however, NRP1 did not appear participate in the evasive mech-
anisms. In a pancreatic neuroendocrine tumor model treated 
with sunitinib, tumor cell local invasion was accelerated by 
cMet activation directly induced by hypoxic stress, but not by 
the direct action of sunitinib on cancer cells (36). In addition, 
VEGF-R2, but not VEGF-R1, usually interacts with and inac-
tivates cMet in mouse models of glioblastoma multiforme, and 
Figure 8. Effect of dual blockade of VEGF-R and cMet on the evasive activation of the colon cancer cells. (A and B) Effect of short-term treatment with 
sunitinib or foretinib on the migration and invasion activities of colon cancer cells. Following the exposure of parental HCT116 and RKO cells to sunitinib 
or foretinib for 48 h, the (A) migration and (B) invasion activities of the cells were evaluated (n=4-6; mean ± standard deviation). *P<0.01 vs. the respective 
dMSO-treated control cells. (C and d) Effect of long-term treatment with foretinib on the migration and invasion activities of colon cancer cells. Parental 
HCT116 and RKO cells were chronically exposed to foretinib for 3 months, and the (C) migration and (d) invasion activities of the cells were evaluated 
(n=4-6; mean ± standard deviation). HPF, high power field. *P<0.01 vs. the respective dMSO-treated control cells. (E and F) Effect of NRP1 blockade on the 
evasive activation of the foretinib-adapted cells. The foretinib-adapted cells were pretreated for 24 h with control (non-immune) IgG or anti-NRP1 neutral-
izing antibody, and the (E) migration and (F) invasion activities of the cells were evaluated (n=4-6; mean ± standard deviation). #P<0.01 vs. the respective 
control IgG-treated cells. VEGF-R, vascular endothelial growth factor receptor; cMet, tyrosine-protein kinase Met; NRP1, neuropilin-1; IgG, immuno-
globulin G; dMSO, dimethylsulfoxide; HCT/ctl, control HCT116 cells; RKO/ctl, control RKO cells; HCT/fore, foretinib-adapted HCT116 cells; RKO/fore, 
foretinib-adapted RKO cells; HPF, high power field.
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blocking VEGF-R2 induces the dissociation of the two recep-
tors and thus activates cMet, leading to increased invasive and 
metastatic activities in vitro and in vivo (35). Notably, NRP1 is 
not involved in the VEGF-R2/cMet system (35).
NRP1 has been suggested to serve critical roles in cancer 
progression, since NRP1 overexpression increased the migra-
tion and invasion activities of gastric and esophageal squamous 
cell carcinoma cell lines (38-40). Additionally, NRP1 is pref-
erentially expressed in metastatic cells. For example, NRP1 
expression has been detected in MdA-MB-231 metastatic 
breast cancer and MBA-MB-435 melanoma cells, but not in 
the MdA-MB-453 non-metastatic cell line and certain non-
metastatic tumors (41,42).
The possible importance of NRP1 in the malignant pheno-
types of tumor cells is supported by several clinical studies, 
including those regarding tumor progression and the poor 
survival of patients (43-47). In advanced colorectal carcinomas, 
patients with tumors expressing high levels of NRP1 exhibited a 
significantly higher incidence of lymph node or liver metastasis 
than did those with tumors expressing low levels of NRP1 (44). 
Increased NRP1 expression occurs in gastrointestinal tumors, 
and this upregulation appears to parallel the invasive behavior 
of the tumor (43). The survival time of patients with tumors 
expressing high NRP1 levels is significantly shorter than that 
of patients with low NRP1 levels (45-47). Therefore, NRP1 is 
suggested to be a prognostic marker in several cancers and an 
important target for cancer therapy.
during anti-angiogenic therapy using VEGF/VEGF-R 
inhibitors, antitumor effects are mainly caused by the reduc-
tion of tumor microvessel density and the resulting hypoxic 
conditions. It is widely accepted that hypoxic stress selects a 
sub-population of tumor cells and activates several phenotypic 
changes by which tumor cells are able to survive and progress 
their malignancy under the hypoxic conditions. However, 
studies have demonstrated that VEGF/VEGF-R inhibitors 
directly act on tumor cells and accelerate their malignant 
phenotypes, independent of hypoxia (18-22). Notably, 
Han et al (48) demonstrated that simple hypoxic stress is 
not sufficient to trigger evasive resistance whereas VEGF-R 
inhibition induces resistance in renal cell carcinoma cells. 
Thus, malignant phenotypes may be accelerated additively or 
synergistically by the direct effects of VEGF/VEGF-R inhibi-
tors and hypoxic stress in the tumor microenvironment in vivo.
In the present study, treatment with sunitinib was demon-
strated to markedly accelerate the evasive activities of the cells 
compared with bevacizumab treatment. This is in agreement 
with previous studies documenting that anti-VEGF antibody 
therapy does not affect metastasis in mouse tumor models, 
whereas VEGF-R tyrosine kinase inhibitors, such as suni-
tinib, promote metastasis (49,50). Additionally, head-to-head 
comparisons between bevacizumab and sunitinib treatments 
have been conducted. In a randomized phase III clinical trial 
in patients with advanced breast cancer, bevacizumab was 
clinically superior to sunitinib (51). In a randomized phase II 
trial in patients with advanced renal-cell carcinoma, treatment 
with bevacizumab produced better efficacy results than were 
obtained with sunitinib (52).
Based on the findings of the present study and evidence 
from several reports indicating that activation of the cMet 
pathway is critical for evasive resistance to VEGF-R-targeting 
therapy (35-37), it appears possible that a dual inhibitor 
of VEGF-R and cMet, such as foretinib, may overcome 
the resistance to VEGF-R inhibitors. Indeed, short-term 
treatment with foretinib completely suppressed the evasive 
activation of colon cancer cells in comparison with sunitinib 
treatment (Fig. 8A and B). However, chronic exposure to 
foretinib induced evasive activation similar to sunitinib treat-
ment (Fig. 8C and d). Notably, blocking NRP1 suppressed 
this activation (Fig. 8E and F). These findings suggest that 
under conditions involving the chronic inhibition of cMet 
and VEGF-R, cancer cells may switch from the NRP1/cMet 
pathway to another pathway that remains to be dependent upon 
NRP1. Therefore, the findings of the present study suggest that 
targeting NRP1 may represent a promising approach for the 
treatment of cancer with drugs targeting VEGF-R and cMet. 
Further studies are required to understand the exact mecha-
nism and molecular interactions of NRP1 under chronic cMet 
and VEGF-R inhibition conditions.
In summary, it is concluded that VEGF/VEGF-R-targeting 
drugs directly induced evasive adaptation in colon cancer cells 
independently of hypoxia. The present study demonstrated that 
sunitinib markedly activated an evasive phenotype through 
an alternative NRP1/HGF/cMet axis, while bevacizumab 
accomplished this through redundant VEGF/VEGF-R1 and 
VEGF-R3 pathways.
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